Research programme: anti-cancer therapeutics - Selvita

Drug Profile

Research programme: anti-cancer therapeutics - Selvita

Alternative Names: A2A/B antagonists - Selvita; Adenosine pathway modulators - Selvita; Dual A2A/A2B adenosine receptor antagonists - Selvita; Dual A2A/A2B antagonists - Selvita; Serine hydroxymethyltransferase 2 inhibitors - Sevita; SHMT2 inhibitors - Selvita

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selvita
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists; Immunomodulators; SHMT-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Dec 2016 Preclinical trials in Cancer in Poland (unspecified route) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top